Comparative Pharmacology
Head-to-head clinical analysis: AEROLATE versus AEROLATE III.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AEROLATE versus AEROLATE III.
AEROLATE vs AEROLATE III
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Theophylline competitively inhibits phosphodiesterase, increasing cAMP levels, and acts as an adenosine receptor antagonist, leading to bronchodilation and reduced airway inflammation.
AEROLATE III (theophylline) is a bronchodilator that inhibits phosphodiesterase, increasing intracellular cAMP levels, leading to relaxation of bronchial smooth muscle and suppression of airway inflammation.
For asthma and COPD: 1-2 inhalations (90 mcg each) via metered-dose inhaler, 2 puffs twice daily, maximum 4 puffs twice daily. For acute exacerbations: 4-8 puffs every 20 minutes for up to 4 hours, then every 1-4 hours as needed.
Inhalation: 2 inhalations (200 mcg) twice daily, max 4 inhalations (400 mcg) per day. Oral: 4 mg twice daily, max 8 mg per day.
None Documented
None Documented
Terminal elimination half-life 12 hours; clinical context: q12h dosing achieves steady-state in 2-3 days
Terminal half-life 12-15 hours; clinically allows twice-daily dosing
Renal (80% as unchanged drug), biliary/fecal (15% as metabolites), 5% other
Renal: 60% unchanged; biliary/fecal: 30% as metabolites; 10% other
Category C
Category C
Bronchodilator
Bronchodilator